

Medical Policy

CAR-T Therapy

Last review date: **5/1/2026**

Prior review date: **10/1/2025**

Applicable Products

Aucatzyl (obecabtagene autoleucel)

Tecartus (brexucabtagene autoleucel)

Breyanzi (lisocabtagene maraleucel)

Yescarta (axicabtagene ciloleucel)

Kymriah (tisagenlecleucel)

Initial Approval Criteria

Coverage may be approved if all of the following are met:

- Drug-specific criteria; **AND**
- If applicable: Trial and failure, intolerance, or a contraindication to the preferred products as listed in the medical drug list

Aucatzyl

- Patient is 18 years of age or older; **AND**
- Patient has relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)

Breyanzi

- Large B-cell Lymphoma (LBCL)
 - Patient is 18 years of age or older; **AND**
 - Patient has large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have one of the following:
 - Refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; **OR**
 - Refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; **OR**
 - Relapsed or refractory disease after 2 or more lines of systemic therapy
- Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
 - Patient is 18 years of age or older; **AND**

- Patient has relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy including, a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor
- Follicular Lymphoma (FL)
 - Patient is 18 years of age or older; **AND**
 - Patient has relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy
- Mantle Cell Lymphoma (MCL)
 - Patient is 18 years of age or older; **AND**
 - Patient has relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor
- Marginal Zone Lymphoma (MZL)
 - Patient is 18 years of age or older; **AND**
 - Patient has relapsed or refractory marginal zone lymphoma (MZL) who have received at least 2 prior lines of systemic therapy

Kymriah

- Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
 - Patient is 25 years of age or younger; **AND**
 - Patient has B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse
- Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma
 - Patient is 18 years of age or older; **AND**
 - Patient has relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma
- Adult Relapsed or Refractory Follicular Lymphoma
 - Patient is 18 years of age or older; **AND**
 - Patient has relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy

Tecartus

- Mantle Cell Lymphoma
 - Patient is 18 years of age or older; **AND**
 - Patient has relapsed or refractory mantle cell lymphoma (MCL)
- Acute Lymphoblastic Leukemia
 - Patient is 18 years of age or older; **AND**
 - Patient has relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)

Yescarta

- Large B-Cell Lymphoma
 - Patient is 18 years of age or older; **AND**
 - One of the following:
 - Patient has large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy; **OR**
 - Patient has relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma
- Follicular Lymphoma
 - Patient is 18 years of age or older; **AND**
 - Patient has relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy

Renewal Criteria

Coverage may be renewed if all of the following are met:

- Patient continues to meet Initial Approval Criteria; **AND**
- Absence of unacceptable toxicity

This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical or other circumstances may warrant individual consideration, based on review of applicable medical records, as well as other regulatory, contractual and/or legal requirements.

Medical policies do not constitute medical advice, nor are they intended to govern the practice of medicine. They are intended to reflect reimbursement and coverage guidelines. Coverage for services may vary for individual members, based on the terms of the benefit contract.